Baxter International Inc
BAX18.960USD
-0.110-0.58%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
9.74BMarket Cap
LossP/E TTM
More Details of Baxter International Inc Company
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
Baxter International Inc Info
Ticker SymbolBAX
Company nameBaxter International Inc
IPO dateJun 20, 2097
CEOHider (Andrew P)
Number of employees38000
Security typeOrdinary Share
Fiscal year-endJun 20
AddressOne Baxter Parkway
CityDEERFIELD
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code60015
Phone12249482000
Websitehttps://www.baxter.com/
Ticker SymbolBAX
IPO dateJun 20, 2097
CEOHider (Andrew P)
Company Executives of Baxter International Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew P. Hider
Mr. Andrew P. Hider
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
368.05K
--
Dr. Jeanne K. Mason, Ph.D.
Dr. Jeanne K. Mason, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
141.67K
+7.47%
Mr. David S. Rosenbloom
Mr. David S. Rosenbloom
Executive Vice President, General Counsel
Executive Vice President, General Counsel
101.60K
-14.01%
Dr. Stephen N. (Steve) Oesterle, M.D.
Dr. Stephen N. (Steve) Oesterle, M.D.
Independent Director
Independent Director
35.70K
+25.18%
Ms. Catherine R. (Cathy) Smith
Ms. Catherine R. (Cathy) Smith
Independent Director
Independent Director
30.23K
+31.17%
Ms. Patricia B. (Patty) Morrison
Ms. Patricia B. (Patty) Morrison
Independent Director
Independent Director
22.94K
+45.58%
Mr. Stephen H. (Steve) Rusckowski
Mr. Stephen H. (Steve) Rusckowski
Independent Director
Independent Director
16.45K
+77.49%
Mr. Jeffrey A. (Jay) Craig
Mr. Jeffrey A. (Jay) Craig
Independent Director
Independent Director
10.65K
+206.88%
Ms. Nancy M. Schlichting
Ms. Nancy M. Schlichting
Lead Independent Director
Lead Independent Director
7.97K
+912.71%
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew P. Hider
Mr. Andrew P. Hider
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
368.05K
--
Dr. Jeanne K. Mason, Ph.D.
Dr. Jeanne K. Mason, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
141.67K
+7.47%
Mr. David S. Rosenbloom
Mr. David S. Rosenbloom
Executive Vice President, General Counsel
Executive Vice President, General Counsel
101.60K
-14.01%
Dr. Stephen N. (Steve) Oesterle, M.D.
Dr. Stephen N. (Steve) Oesterle, M.D.
Independent Director
Independent Director
35.70K
+25.18%
Ms. Catherine R. (Cathy) Smith
Ms. Catherine R. (Cathy) Smith
Independent Director
Independent Director
30.23K
+31.17%
Ms. Patricia B. (Patty) Morrison
Ms. Patricia B. (Patty) Morrison
Independent Director
Independent Director
22.94K
+45.58%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Infusion Therapies and Technologies
1.02B
36.44%
Care and Connectivity Solutions
474.00M
16.87%
Injectables and Anesthesia
332.00M
11.81%
Advanced Surgery
296.00M
10.53%
Front Line Care
293.00M
10.43%
Other
391.00M
13.91%
By RegionUSD
Name
Revenue
Proportion
United States
1.54B
54.66%
International
1.27B
45.34%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Infusion Therapies and Technologies
1.02B
36.44%
Care and Connectivity Solutions
474.00M
16.87%
Injectables and Anesthesia
332.00M
11.81%
Advanced Surgery
296.00M
10.53%
Front Line Care
293.00M
10.43%
Other
391.00M
13.91%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
12.11%
Dodge & Cox
11.17%
Pzena Investment Management, LLC
11.16%
BlackRock Institutional Trust Company, N.A.
6.09%
BlackRock Financial Management, Inc.
4.80%
Other
54.66%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
12.11%
Dodge & Cox
11.17%
Pzena Investment Management, LLC
11.16%
BlackRock Institutional Trust Company, N.A.
6.09%
BlackRock Financial Management, Inc.
4.80%
Other
54.66%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
47.20%
Investment Advisor
44.83%
Hedge Fund
2.90%
Research Firm
2.48%
Pension Fund
1.50%
Insurance Company
1.45%
Bank and Trust
1.22%
Sovereign Wealth Fund
1.14%
Individual Investor
0.46%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1743
527.76M
108.76%
+72.60K
2025Q3
1826
527.84M
110.04%
+1.85M
2025Q2
1880
509.50M
105.73%
+4.72M
2025Q1
1916
504.93M
105.92%
-38.38M
2024Q4
1965
494.73M
105.04%
+14.02M
2024Q3
1980
482.92M
103.29%
+12.67M
2024Q2
2019
470.33M
102.19%
-1.85M
2024Q1
2069
469.00M
102.47%
-52.95M
2023Q4
2111
469.21M
101.33%
+9.34M
2023Q3
2090
463.57M
98.58%
+5.62M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
61.95M
12.06%
+1.13M
+1.85%
Jun 30, 2025
Dodge & Cox
52.12M
10.15%
+662.70K
+1.29%
Jun 30, 2025
Pzena Investment Management, LLC
55.46M
10.8%
+16.12M
+40.98%
Aug 31, 2025
BlackRock Institutional Trust Company, N.A.
29.85M
5.81%
-423.57K
-1.40%
Jun 30, 2025
BlackRock Financial Management, Inc.
18.73M
3.65%
+742.99K
+4.13%
Jun 30, 2025
State Street Investment Management (US)
21.94M
4.27%
+170.66K
+0.78%
Jun 30, 2025
T. Rowe Price Associates, Inc.
21.21M
4.13%
+1.64M
+8.40%
Jun 30, 2025
Geode Capital Management, L.L.C.
12.88M
2.51%
+326.65K
+2.60%
Jun 30, 2025
BlackRock Investment Management, LLC
7.81M
1.52%
+818.08K
+11.70%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Large Cap Value Active ETF
2.23%
First Trust Indxx Medical Devices ETF
1.69%
Invesco Raymond James SB-1 Equity ETF
1.5%
State Street SPDR S&P Health Care Equipment ETF
1.37%
Invesco S&P 500 Equal Weight Health Care ETF
1.26%
Franklin US Dividend Booster Index ETF
1.26%
iShares U.S. Medical Devices ETF
1.13%
Invesco Zacks Multi-Asset Income ETF
0.8%
Humankind US Stock ETF
0.76%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
0.57%
View more
iShares Large Cap Value Active ETF
Proportion2.23%
First Trust Indxx Medical Devices ETF
Proportion1.69%
Invesco Raymond James SB-1 Equity ETF
Proportion1.5%
State Street SPDR S&P Health Care Equipment ETF
Proportion1.37%
Invesco S&P 500 Equal Weight Health Care ETF
Proportion1.26%
Franklin US Dividend Booster Index ETF
Proportion1.26%
iShares U.S. Medical Devices ETF
Proportion1.13%
Invesco Zacks Multi-Asset Income ETF
Proportion0.8%
Humankind US Stock ETF
Proportion0.76%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
Proportion0.57%
Dividend
A total of
2.75B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Nov 11, 2025
BAX.NB Final Cash Dividend of gross USD 0.01 paid on Jan 02, 2026 going ex on Nov 28, 2025 with reinvestment option
Nov 28, 2025
Jan 02, 2026
Nov 28, 2025
Jul 14, 2025
BAX.NB Interim Cash Dividend of gross USD 0.17 paid on Oct 01, 2025 going ex on Aug 29, 2025 with reinvestment option
Aug 29, 2025
Oct 01, 2025
Aug 29, 2025
May 06, 2025
BAX.NB Interim Cash Dividend of gross USD 0.17 paid on Jul 01, 2025 going ex on May 30, 2025 with reinvestment option
May 30, 2025
Jul 01, 2025
May 30, 2025
Feb 11, 2025
BAX.NB Interim Cash Dividend of gross USD 0.17 paid on Apr 01, 2025 going ex on Feb 28, 2025 with reinvestment option
Feb 28, 2025
Apr 01, 2025
Feb 28, 2025
Nov 11, 2024
BAX.NB Final Cash Dividend of gross USD 0.17 paid on Jan 02, 2025 going ex on Nov 29, 2024 with reinvestment option
Nov 29, 2024
Jan 02, 2025
Nov 29, 2024
Jul 16, 2024
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Oct 01, 2024 going ex on Aug 30, 2024 with reinvestment option
Aug 30, 2024
Oct 01, 2024
Aug 30, 2024
May 07, 2024
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Jul 01, 2024 going ex on May 31, 2024 with reinvestment option
May 31, 2024
Jul 01, 2024
May 31, 2024
Feb 12, 2024
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Apr 01, 2024 going ex on Feb 29, 2024 with reinvestment option
Mar 01, 2024
Apr 01, 2024
Feb 29, 2024
Nov 14, 2023
BAX.NB Final Cash Dividend of gross USD 0.29 paid on Jan 02, 2024 going ex on Nov 30, 2023 with reinvestment option
Dec 01, 2023
Jan 02, 2024
Nov 30, 2023
Jul 18, 2023
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Oct 02, 2023 going ex on Aug 31, 2023 with reinvestment option
Sep 01, 2023
Oct 02, 2023
Aug 31, 2023
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Baxter International Inc?
The top five shareholders of Baxter International Inc are:
The Vanguard Group, Inc. holds 61.95M shares, accounting for 12.06% of the total shares.
Dodge & Cox holds 52.12M shares, accounting for 10.15% of the total shares.
Pzena Investment Management, LLC holds 55.46M shares, accounting for 10.80% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 29.85M shares, accounting for 5.81% of the total shares.
BlackRock Financial Management, Inc. holds 18.73M shares, accounting for 3.65% of the total shares.
The Vanguard Group, Inc. holds 61.95M shares, accounting for 12.06% of the total shares.
Dodge & Cox holds 52.12M shares, accounting for 10.15% of the total shares.
Pzena Investment Management, LLC holds 55.46M shares, accounting for 10.80% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 29.85M shares, accounting for 5.81% of the total shares.
BlackRock Financial Management, Inc. holds 18.73M shares, accounting for 3.65% of the total shares.
What are the top three shareholder types of Baxter International Inc?
The top three shareholder types of Baxter International Inc are:
The Vanguard Group, Inc.
Dodge & Cox
Pzena Investment Management, LLC
The Vanguard Group, Inc.
Dodge & Cox
Pzena Investment Management, LLC
How many institutions hold shares of Baxter International Inc (BAX)?
As of 2025Q4, 1743 institutions hold shares of Baxter International Inc, with a combined market value of approximately 527.76M, accounting for 108.76% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.28%.
What is the biggest source of revenue for Baxter International Inc?
In FY2025Q2, the Infusion Therapies and Technologies business generated the highest revenue for Baxter International Inc, amounting to 1.02B and accounting for 36.44% of total revenue.
